96 related articles for article (PubMed ID: 20841935)
1. [Pharmacokinetic study of S-1 for the treatment of peritoneal metastasis from colon cancer--using a mouse peritoneal metastasis model].
Sadahiro S; Suzuki T; Maeda Y; Tanaka A; Okada K; Kanoda H; Kamijo A
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1725-8. PubMed ID: 20841935
[TBL] [Abstract][Full Text] [Related]
2. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer.
Yamagata S; Nakata B; Hirakawa K
Oncol Rep; 2004 Nov; 12(5):973-8. PubMed ID: 15492780
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
[TBL] [Abstract][Full Text] [Related]
4. [Concentration of FT and CDHP and 5-FU in the ascites fluid of patient with peritoneal carcinomatosis after new anti-cancer drug TS-1 oral administration].
Iizuka R; Takahashi S; Kakihara N; Matsumura H; Takenaka A
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1251-3. PubMed ID: 12146009
[No Abstract] [Full Text] [Related]
5. Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1.
Tsuruoka Y; Kamano T; Kitajima M; Kawai K; Watabe S; Ochiai T; Sakamoto K; Shirasaka T
Anticancer Drugs; 2006 Apr; 17(4):393-9. PubMed ID: 16549996
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.
Oshima T; Yamada R; Hatori S; Kunisaki C; Imada T
Oncol Rep; 2006 Aug; 16(2):361-6. PubMed ID: 16820916
[TBL] [Abstract][Full Text] [Related]
9. Effect of combination therapy with UFT plus cisplatin (UFTP) on the survival of mice in the experimental model for wide-spread metastasis in the peritoneal cavity of gastrointestinal cancer using colon 26 PMF-15 cells.
Kurihara M; Uchida J; Fujioka A; Kato T; Ohshimo H; Abe M; Takeda S; Fukushima M
Anticancer Res; 1997; 17(3C):2217-20. PubMed ID: 9216691
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
Shirasaka T; Nakano K; Takechi T; Satake H; Uchida J; Fujioka A; Saito H; Okabe H; Oyama K; Takeda S; Unemi N; Fukushima M
Cancer Res; 1996 Jun; 56(11):2602-6. PubMed ID: 8653704
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetics of S-1].
Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
[TBL] [Abstract][Full Text] [Related]
12. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model.
Cao S; Lu K; Tóth K; Slocum HK; Shirasaka T; Rustum YM
Clin Cancer Res; 1999 Feb; 5(2):267-74. PubMed ID: 10037174
[TBL] [Abstract][Full Text] [Related]
13. [Successful low-dose TS-1 administration in an elderly colon cancer patient with liver metastasis].
Ohnishi T; Kanoh T; Kimura Y; Iwazawa T; Tono T; Nakano Y; Yano K; Monden T
Gan To Kagaku Ryoho; 2007 Apr; 34(4):623-5. PubMed ID: 17431353
[TBL] [Abstract][Full Text] [Related]
14. [A case of advanced colon cancer with peritoneal dissemination completely responding to TS-1].
Taguchi S; Osugi H; Takemura M; Lee S; Kaneko M; Tanaka Y; Fujiwara Y; Nishizawa S; Iwasaki H
Gan To Kagaku Ryoho; 2004 Feb; 31(2):259-61. PubMed ID: 14997764
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
Cohen SJ; Leichman CG; Yeslow G; Beard M; Proefrock A; Roedig B; Damle B; Letrent SP; DeCillis AP; Meropol NJ
Clin Cancer Res; 2002 Jul; 8(7):2116-22. PubMed ID: 12114411
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma.
Tachimori A; Yamada N; Amano R; Ohira M; Hirakawa K
Anticancer Res; 2008; 28(2A):629-38. PubMed ID: 18507001
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of S-1 on DMH induced colon cancer in rats.
Tsunoda A; Shibusawa M; Tsunoda Y; Yokoyama N; Nakao K; Kusano M; Nomura N; Nagayama S; Takechi T
Anticancer Res; 1998; 18(2A):1137-41. PubMed ID: 9615778
[TBL] [Abstract][Full Text] [Related]
18. [Combined effect of S-1 and CDDP as a modulator for colon 26 liver metastasis].
Kitamura M; Arai K; Iwasaki Y; Takahashi T; Saitoh K; Fujii T; Shirasaka T
Gan To Kagaku Ryoho; 2000 Apr; 27(4):559-63. PubMed ID: 10790998
[TBL] [Abstract][Full Text] [Related]
19. Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report.
Sueda T; Kudo T; Sakai D; Uemura M; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Ezoe S; Matsumoto K; Doki Y; Mori M; Satoh T
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1321-4. PubMed ID: 25374410
[TBL] [Abstract][Full Text] [Related]
20. Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil.
Mori T; Fujiwara Y; Yano M; Tamura S; Yasuda T; Takiguchi S; Monden M
Oncology; 2003; 64(2):176-82. PubMed ID: 12566916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]